Michael Greiner Sells 1,939 Shares of AngioDynamics, Inc. (ANGO) Stock
AngioDynamics, Inc. (NASDAQ:ANGO) CFO Michael Greiner sold 1,939 shares of AngioDynamics stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $21.53, for a total value of $41,746.67. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Shares of NASDAQ:ANGO opened at $21.38 on Friday. AngioDynamics, Inc. has a fifty-two week low of $15.16 and a fifty-two week high of $24.49. The stock has a market capitalization of $805.91 million, a price-to-earnings ratio of 28.89 and a beta of 0.75. The company has a quick ratio of 1.55, a current ratio of 2.64 and a debt-to-equity ratio of 0.16.
AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Thursday, September 27th. The medical instruments supplier reported $0.16 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.02). AngioDynamics had a return on equity of 5.44% and a net margin of 4.62%. The company had revenue of $85.34 million during the quarter, compared to analyst estimates of $84.05 million. During the same period in the prior year, the firm earned $0.13 EPS. AngioDynamics’s quarterly revenue was down .1% on a year-over-year basis. As a group, analysts predict that AngioDynamics, Inc. will post 0.85 EPS for the current fiscal year.
A number of analysts have weighed in on the company. BidaskClub raised AngioDynamics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 27th. Zacks Investment Research raised AngioDynamics from a “sell” rating to a “hold” rating in a research report on Tuesday, September 11th. Four investment analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. AngioDynamics currently has an average rating of “Buy” and a consensus price target of $18.44.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
Featured Story: Inflation
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.